DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Rimassa L, Porta C, Borbath I , et al.
Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT).
J Clin Oncol 2012;
30 (Suppl): Abstract 4006
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.